SCHEMBL12425646

SCHEMBL12425646

CC(C)(C)[Si](OCc1cc(Br)c(OCc2ccccc2)cc1F)(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
CCR5 P51681 2/20 0.37
RAB9A P51151 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM1A O60341 6/20 0.36
PTGER1 P34995 1/20 0.35
PTPN1 P18031 1/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX5AP P20292 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34
STAT3 P40763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7537935 0.76 MAOB (0.41) LMNAALDH1A1HTR2AMEN1KMT2A
SCHEMBL12425644 0.74 CLCN2 (0.32) ALDH1A1HTTGAA
SCHEMBL16636496 0.74 RAB9A (0.50) RAB9AHTR2AHTR2CSMN1; SMN2KDM1A
SCHEMBL1314001 0.74 AGXT (0.42) LMNAALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL15610599 0.73 MEN1 (0.38) HTR2AHTR2CPTPN1HTTMEN1
SCHEMBL19000495 0.71 ALOX5AP (0.33) SMN1; SMN2KDM1AHTTALOX5APMAPT
SCHEMBL31611455 0.71 RAB9A (0.48) CCR5RAB9ASMN1; SMN2KDM1APTGER1
SCHEMBL10204739 0.71 NUDT1 (0.39) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL5549025 0.71 TACR1 (0.35) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL4587307 0.70 IDO1 (0.42) LMNARAB9ASMN1; SMN2HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977466-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2011-07-12 US disclosed
US-7772407-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2010-08-10 US disclosed
US-20090069252-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-12 US disclosed
US-20070161787-A1 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2007-07-12 US disclosed
US-7202350-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161787-A1 C-glycoside derivatives and salts thereof SLC5A1, SLC5A2, SLC2A1 LMNA 3360/4885CCR5 1766/4885RAB9A 1225/4885
US-20090069252-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF SLC5A1, SLC5A2, SLC2A1 LMNA 3360/4885CCR5 1766/4885RAB9A 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.